| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J9299 |
Injection, nivolumab, 1 mg |
935 |
654 |
$6.42M |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
4,401 |
2,971 |
$3.84M |
| J9271 |
Injection, pembrolizumab, 1 mg |
261 |
211 |
$3.10M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
15,437 |
9,573 |
$1.69M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
18,519 |
17,228 |
$1.39M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
20,027 |
19,562 |
$1.04M |
| J2505 |
Injection, pegfilgrastim, 6 mg |
304 |
243 |
$874K |
| J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
710 |
544 |
$530K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
6,802 |
4,581 |
$442K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
6,803 |
3,532 |
$438K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,551 |
3,532 |
$413K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
9,415 |
5,209 |
$295K |
| J0897 |
Injection, denosumab, 1 mg |
194 |
176 |
$293K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
12,575 |
8,511 |
$204K |
| 96417 |
|
2,849 |
1,954 |
$134K |
| 96415 |
|
1,581 |
1,092 |
$49K |
| 96402 |
|
1,366 |
1,264 |
$33K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
7,222 |
3,922 |
$30K |
| 96401 |
|
473 |
310 |
$28K |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
15 |
12 |
$28K |
| Q5106 |
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units |
120 |
51 |
$26K |
| 96367 |
|
742 |
528 |
$21K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
411 |
204 |
$21K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
850 |
820 |
$18K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
152 |
152 |
$12K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
119 |
119 |
$6K |
| 99233 |
Prolong inpt eval add15 m |
99 |
50 |
$5K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
2,602 |
2,294 |
$5K |
| 99223 |
Prolong inpt eval add15 m |
31 |
31 |
$4K |
| 99205 |
Prolong outpt/office vis |
26 |
26 |
$4K |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
23 |
12 |
$992.44 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
741 |
500 |
$592.00 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
148 |
142 |
$560.53 |
| J9045 |
Injection, carboplatin, 50 mg |
14 |
12 |
$506.54 |
| J3489 |
Injection, zoledronic acid, 1 mg |
14 |
12 |
$457.48 |
| 96411 |
|
34 |
24 |
$425.57 |
| J9190 |
Injection, fluorouracil, 500 mg |
22 |
12 |
$329.55 |
| 96523 |
|
24 |
14 |
$161.24 |